333 Changes in proteomic markers after injections of personal AV-GBM-1 dendritic cell/tumor initiating cell vaccines in a phase II trial in patients with newly diagnosed glioblastoma

• Gabriel Nistor,
• Robert Dillman,
• Aleksandra Poole,
• Daniela Bota,
• David Piccioni,
• Christopher Duma,
• Renato LaRocca,
• Santosh Kesari,
• Jose Carrillo,
• Robert Aiken,
• Frank Hsu,
• Xiao-Tang Kong,
• Thomas Taylor,
• Mehrdad Abedi,
• Candace Hsieh

Affiliations

Gabriel Nistor

Aff7 Neostem OncologyLLC Irvine United States

Robert Dillman

Aff7 Neostem OncologyLLC Irvine United States

Aleksandra Poole

Aff1 grid.417388.10000000403674756Caladrius Biosciences, Inc. Irvine CA USA

Daniela Bota

1Unviersity of California, Irvine, Orange, USA

David Piccioni

3UCSD, San Diego, CA, USA

Christopher Duma

4Hoag Hospital, Newport Beach, CA, USA

Renato LaRocca

5Norton Cancer Center, Louisville, KY, USA

Santosh Kesari

6John Wayne Cancer Institute, Santa Monica, California, USA

Jose Carrillo

6John Wayne Cancer Institute, Santa Monica, California, USA

Robert Aiken

8Rutgers, New Brunswick, NJ, USA

Frank Hsu

2UCI, Orange, USA

Xiao-Tang Kong

2UCI, Orange, USA

Thomas Taylor

Clinical Radiology, Ninewells Hospital and Medical School, Dundee, UK

Mehrdad Abedi

6UC Davis, Sacramento, CA, USA

Candace Hsieh

8AIVITA Biomedical, Inc, Irvine, CA, USA